Applying ApoB to Clinical Practice: A Critique of Current Arguments Against Its Routine Use

This commentary by Allan Sniderman — one of the principal advocates for apolipoprotein B as the primary cardiovascular risk marker — systematically addresses and rebuts the main arguments used at the time to justify not adopting ApoB in routine clinical practice.

The counterarguments addressed include: LDL-C performs well enough; ApoB is technically difficult to measure; guidelines do not recommend it; and adding new tests creates confusion. Sniderman argues each falls short. LDL-C performs poorly in the one-third of patients with discordance between cholesterol content and particle count. Automated ApoB immunoassays are cheap, standardized, and clinically available. Guideline lag reflects inertia rather than evidence. And confusing LDL-C with ApoB at the bedside is a clinical reasoning failure, not a test problem.

The core argument — that ApoB directly measures the number of atherogenic particles entering the arterial wall, while LDL-C measures the cholesterol within those particles — remains one of the most clinically important distinctions in preventive cardiology. In patients with insulin resistance, metabolic syndrome, or small dense LDL, LDL-C systematically underestimates cardiovascular risk while ApoB correctly captures it.

As a commentary, this study provides no new empirical data. Its value lies in the clarity of the conceptual argument and its historical role in pressing the evidence-informed case for ApoB adoption into clinical testing.

We rate the evidence limited. A well-argued advocacy commentary from a leading authority — no new data, but a clear articulation of why ApoB supersedes LDL-C as a primary target for atherogenic particle burden assessment.